Cargando…

Initial Results after the Implementation of an Edge-To-Edge Transcatheter Tricuspid Valve Repair Program

Transcatheter tricuspid valve repair (TTVr) has emerged as an alternative for the treatment of severe tricuspid regurgitation (TR). We report our initial experience with an edge-to-edge TTVr system in a high-volume institution. Methods: We included consecutive patients who underwent edge-to-edge TTV...

Descripción completa

Detalles Bibliográficos
Autores principales: Cepas-Guillen, Pedro Luis, de la Fuente Mancera, Juan Carlos, Guzman Bofarull, Joan, Farrero, Marta, Regueiro, Ander, Brugaletta, Salvatore, Ibañez, Cristina, Sanchis, Laura, Sitges, Marta, Sabate, Manel, Freixa, Xavier
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8471561/
https://www.ncbi.nlm.nih.gov/pubmed/34575362
http://dx.doi.org/10.3390/jcm10184252
_version_ 1784574498619523072
author Cepas-Guillen, Pedro Luis
de la Fuente Mancera, Juan Carlos
Guzman Bofarull, Joan
Farrero, Marta
Regueiro, Ander
Brugaletta, Salvatore
Ibañez, Cristina
Sanchis, Laura
Sitges, Marta
Sabate, Manel
Freixa, Xavier
author_facet Cepas-Guillen, Pedro Luis
de la Fuente Mancera, Juan Carlos
Guzman Bofarull, Joan
Farrero, Marta
Regueiro, Ander
Brugaletta, Salvatore
Ibañez, Cristina
Sanchis, Laura
Sitges, Marta
Sabate, Manel
Freixa, Xavier
author_sort Cepas-Guillen, Pedro Luis
collection PubMed
description Transcatheter tricuspid valve repair (TTVr) has emerged as an alternative for the treatment of severe tricuspid regurgitation (TR). We report our initial experience with an edge-to-edge TTVr system in a high-volume institution. Methods: We included consecutive patients who underwent edge-to-edge TTVr systems. The primary efficacy endpoint was a reduction in the TR of at least one grade. The primary safety endpoint was procedure-related clinical serious adverse events. Results: A total of 28 patients underwent TTVr with edge-to-edge systems. All patients presented with at least severe TR with a high impact on quality of life (82% of patients in NYHA class ≥ III). The Triclip system was the most used device (89%). The primary efficacy endpoint was met in all patients. Only one patient experienced a procedural complication (femoral pseudoaneurysm). At three-month follow-up, 83% of patients were in NYHA I or II (18% baseline vs. 83% 3 months follow-up; p < 0.001). Echocardiography follow-up showed residual TR ≤ 2 in 79% of patients (paired p < 0.001). At the maximum follow-up (median follow up = 372 days), no patients had died. Conclusions: Edge-to-edge TTVr systems seem to represent a very valid alternative to prevent morbidity and mortality associated with TR as depicted by the favorable efficacy and safety.
format Online
Article
Text
id pubmed-8471561
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-84715612021-09-28 Initial Results after the Implementation of an Edge-To-Edge Transcatheter Tricuspid Valve Repair Program Cepas-Guillen, Pedro Luis de la Fuente Mancera, Juan Carlos Guzman Bofarull, Joan Farrero, Marta Regueiro, Ander Brugaletta, Salvatore Ibañez, Cristina Sanchis, Laura Sitges, Marta Sabate, Manel Freixa, Xavier J Clin Med Article Transcatheter tricuspid valve repair (TTVr) has emerged as an alternative for the treatment of severe tricuspid regurgitation (TR). We report our initial experience with an edge-to-edge TTVr system in a high-volume institution. Methods: We included consecutive patients who underwent edge-to-edge TTVr systems. The primary efficacy endpoint was a reduction in the TR of at least one grade. The primary safety endpoint was procedure-related clinical serious adverse events. Results: A total of 28 patients underwent TTVr with edge-to-edge systems. All patients presented with at least severe TR with a high impact on quality of life (82% of patients in NYHA class ≥ III). The Triclip system was the most used device (89%). The primary efficacy endpoint was met in all patients. Only one patient experienced a procedural complication (femoral pseudoaneurysm). At three-month follow-up, 83% of patients were in NYHA I or II (18% baseline vs. 83% 3 months follow-up; p < 0.001). Echocardiography follow-up showed residual TR ≤ 2 in 79% of patients (paired p < 0.001). At the maximum follow-up (median follow up = 372 days), no patients had died. Conclusions: Edge-to-edge TTVr systems seem to represent a very valid alternative to prevent morbidity and mortality associated with TR as depicted by the favorable efficacy and safety. MDPI 2021-09-19 /pmc/articles/PMC8471561/ /pubmed/34575362 http://dx.doi.org/10.3390/jcm10184252 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Cepas-Guillen, Pedro Luis
de la Fuente Mancera, Juan Carlos
Guzman Bofarull, Joan
Farrero, Marta
Regueiro, Ander
Brugaletta, Salvatore
Ibañez, Cristina
Sanchis, Laura
Sitges, Marta
Sabate, Manel
Freixa, Xavier
Initial Results after the Implementation of an Edge-To-Edge Transcatheter Tricuspid Valve Repair Program
title Initial Results after the Implementation of an Edge-To-Edge Transcatheter Tricuspid Valve Repair Program
title_full Initial Results after the Implementation of an Edge-To-Edge Transcatheter Tricuspid Valve Repair Program
title_fullStr Initial Results after the Implementation of an Edge-To-Edge Transcatheter Tricuspid Valve Repair Program
title_full_unstemmed Initial Results after the Implementation of an Edge-To-Edge Transcatheter Tricuspid Valve Repair Program
title_short Initial Results after the Implementation of an Edge-To-Edge Transcatheter Tricuspid Valve Repair Program
title_sort initial results after the implementation of an edge-to-edge transcatheter tricuspid valve repair program
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8471561/
https://www.ncbi.nlm.nih.gov/pubmed/34575362
http://dx.doi.org/10.3390/jcm10184252
work_keys_str_mv AT cepasguillenpedroluis initialresultsaftertheimplementationofanedgetoedgetranscathetertricuspidvalverepairprogram
AT delafuentemancerajuancarlos initialresultsaftertheimplementationofanedgetoedgetranscathetertricuspidvalverepairprogram
AT guzmanbofarulljoan initialresultsaftertheimplementationofanedgetoedgetranscathetertricuspidvalverepairprogram
AT farreromarta initialresultsaftertheimplementationofanedgetoedgetranscathetertricuspidvalverepairprogram
AT regueiroander initialresultsaftertheimplementationofanedgetoedgetranscathetertricuspidvalverepairprogram
AT brugalettasalvatore initialresultsaftertheimplementationofanedgetoedgetranscathetertricuspidvalverepairprogram
AT ibanezcristina initialresultsaftertheimplementationofanedgetoedgetranscathetertricuspidvalverepairprogram
AT sanchislaura initialresultsaftertheimplementationofanedgetoedgetranscathetertricuspidvalverepairprogram
AT sitgesmarta initialresultsaftertheimplementationofanedgetoedgetranscathetertricuspidvalverepairprogram
AT sabatemanel initialresultsaftertheimplementationofanedgetoedgetranscathetertricuspidvalverepairprogram
AT freixaxavier initialresultsaftertheimplementationofanedgetoedgetranscathetertricuspidvalverepairprogram